טוען...
Advances in treatment of chronic myelogenous leukemia – new treatment options with tyrosine kinase inhibitors
Imatinib is considered standard therapy for patients with chronic myelogenous leukemia (CML), inducing a high rate of hematologic and cytogenetic responses. Despite these excellent results, several patients develop resistance to imatinib. Mechanisms of resistance are varied and include BCR-ABL1 kina...
שמור ב:
| Main Authors: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2009
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4109296/ https://ncbi.nlm.nih.gov/pubmed/20017607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428190903383427 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|